RxDoctor Payments Data

Gary Hopen, MD

Ophthalmology · Hollywood, FLNPI 1285741298

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.5% of the total across 55 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Mallinckrodt Hospital Products Inc. at 24.5% of the total. 2025 is the largest year on record at $353, 5.4 times the $66 reported in 2019. That places this record below the midpoint for ophthalmology clinicians in FL, where the typical reported total is $1,824.

$1,238in general payments, 2019–2025

Across 55 payments — averaging $22.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mallinckrodt Hospital Products Inc.$304
  • Alcon$210
  • AbbVie$158
  • Amgen$93
  • Aerie Pharmaceuticals, Inc.$72
  • Bausch & Lomb Americas Inc.$69
  • plus $333 from 10 others

What the payments were for

  • Food & beverage$1,19596%
  • Education$242%
  • Gifts$192%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,238 in reported general payments places this provider in the 40th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida →

Medicare billing

Part B allowed, 2024
$188,370
Medicare patients
643
Services billed
1,978

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine41$36,150
LumiganBimatoprost35$15,602
CombiganBrimonidine Tartrate/Timolol23$13,031
Latanoprost557$5,479
Prednisolone Acetate148$5,224
Travoprost14$3,648
MoxifloxacinMoxifloxacin Hcl117$2,723
Ketorolac Tromethamine117$2,251
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat101$1,630
Brimonidine Tartrate87$1,161
Dorzolamide Hcl33$645
Timolol Maleate36$594
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha44$525

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$158$64,78399 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Hollywood

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →